Considering the NECTIN4 expression in melanoma cells and their sensitivity to MMAE, enfortumab vedotin may act as an effective anti-tumor drug against melanoma, and BRAFi-resistant cells are more likely to be sensitive to it. The gene discussed is NECTIN4; the disease is melanoma.